Friedreich's Ataxia Research Alliance (FARA)

Provides Friedreich's ataxia-specific funding within a United States biomedical foundation focused on this disease area.

Friedreich's Ataxia Research Alliance (FARA) is a US-based 501(c)(3) patient advocacy nonprofit founded in 1998. It is dedicated to accelerating treatments and a cure for Friedreich's ataxia, a progressive neurodegenerative and cardiac disease, and it operates a global research program that accepts investigators from any country.

Its funding spans basic, translational, and clinical science, with awards ranging from $50,000 graduate and training support to $200,000-a-year named translational awards, plus directed research initiatives and institutional partnerships with Penn/CHOP and the Broad Institute. The portfolio includes the General Research Grant, Award for Innovative Mindset, Named Research Awards, Clinician Scientist Development Award, Postdoctoral and Graduate Training Awards, Request for Proposals, and the FARA Fellow Program. Indirect costs are not funded.

Applicants are expected to show clear scientific significance, strong methods, and realistic milestones, because FARA uses NIH-style review criteria and ties continuation to progress reporting. The organization is especially relevant to researchers already working in the FA community, including industry teams with a credible role in the disease area. Its support is narrowly disease-specific but genuinely international in reach.